Cyclerion Therapeutics, Inc.
https://www.cyclerion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cyclerion Therapeutics, Inc.
Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs
The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.
Cyclerion Looking To Partner Praliciguat Despite Phase II Fail In Diabetic Nephropathy
The Ironwood spinout thinks its sGC stimulator demonstrated benefit in reducing urine albumin levels in DN patients; notes data improve markedly if one outlier trial site is excluded.
PARAGON-HF: Novartis Hangs Onto Hope For Entresto In HFpEF
Despite Phase III miss, Novartis is hopeful that the totality of the evidence will secure it at least a limited label expansion to a sizable but harder to treat portion of the heart failure market than Entresto already serves.
Finance Watch: A Rough Week To End A Bad Month For Biotech Stocks
Public Company Edition: The prior day's after-hours bad news sent biotech stocks lower on 9 August, and IPOs are taking a breather with the NBI down 2.1% over the past month. However, already public companies are raising cash, including Allakos and Ironwood at $350m each.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals